NeoPharm investors exact revenge on trial failure

NeoPharm was also dealing with the ugly aftermath of its own trial failure this morning. Its stock plunged more than 70 percent after the company announced that its experimental therapy for malignant tumors of the central nervous system had failed a Phase III trial, failing to prove more effective than an existing therapy. Officials will also ponder the fate of cintredekin besudotox with regulators and researchers.

"Top-line data suggests that cintredekin besudotox, while comparable, was not statistically superior to Gliadel," said Guillermo Herrera, Neopharm's president and CEO. "We will continue to work with our Scientific Advisory Board and the FDA to determine the best path forward."

- see this press release on the trial
- here's the AP report on the data

Suggested Articles

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.

The trial has been paused since early September while FDA reviews the safety of the vaccine in light of a reported case of an inflammatory disorder.

Biogen is cutting its experimental multiple sclerosis drug opicinumab as well as an spinal muscular atrophy candidate amid a third-quarter clear-out.